Venturi Wealth Management LLC Has $152,000 Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Venturi Wealth Management LLC lifted its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 28.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,000 shares of the company’s stock after buying an additional 2,000 shares during the period. Venturi Wealth Management LLC’s holdings in Cellebrite DI were worth $152,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in CLBT. Point72 Asia Singapore Pte. Ltd. lifted its position in shares of Cellebrite DI by 59.6% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock worth $33,000 after acquiring an additional 1,017 shares during the period. Public Employees Retirement Association of Colorado acquired a new position in shares of Cellebrite DI in the second quarter valued at $71,000. Pathway Financial Advisers LLC lifted its position in Cellebrite DI by 1,583.8% in the third quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock worth $74,000 after purchasing an additional 4,118 shares during the period. nVerses Capital LLC acquired a new stake in Cellebrite DI during the second quarter worth $103,000. Finally, TD Asset Management Inc bought a new stake in Cellebrite DI in the 2nd quarter valued at $121,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on CLBT. Needham & Company LLC lifted their target price on shares of Cellebrite DI from $17.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Lake Street Capital lifted their price objective on Cellebrite DI from $13.50 to $17.00 and gave the company a “buy” rating in a report on Friday, August 16th. Craig Hallum upped their price objective on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. TD Cowen raised their target price on Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Finally, JPMorgan Chase & Co. upped their price target on Cellebrite DI from $21.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $20.29.

Cellebrite DI Price Performance

NASDAQ CLBT opened at $17.81 on Thursday. The stock’s 50 day simple moving average is $17.68 and its 200 day simple moving average is $14.45. Cellebrite DI Ltd. has a one year low of $7.61 and a one year high of $21.00. The firm has a market cap of $3.67 billion, a PE ratio of -11.49, a price-to-earnings-growth ratio of 2.61 and a beta of 1.50.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The company had revenue of $106.90 million during the quarter, compared to analyst estimates of $102.06 million. During the same period last year, the company posted $0.09 earnings per share. The firm’s quarterly revenue was up 27.0% compared to the same quarter last year. As a group, equities analysts expect that Cellebrite DI Ltd. will post 0.31 earnings per share for the current year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.